Authors: Emily M.Webster, Ghanshyam S.Yadav, Stefan Gysler, Blair McNamara, Jonathan Black, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Christopher K. Arkfeld, Vaagn Andikyan, Gulden Menderes, Gloria Huang, Masoud Azodi, Dan-Arin Silasi, Alessandro D.Santin,Peter E.Schwartz, Elena S.Ratner, Gary Altwerger Published in Gynecologic Oncology Reports November 2020 Abstract Research within a gynecologic oncology population has lagged behind…
Author: Kevin M Takakuwa, Frances S Shofer, Raquel M Schears Published in The American Journal of Emergency Medicine January 2020 Introduction Medical cannabis is legal in 33 US states [ 1 ] but remains federally illegal. The majority of legal states require physicians to provide cannabis recommendations in order for patients to have access to it….
Dr. Kevin M.Takakuwa details the history of the SCC, which is the first and oldest U.S. medical organization promoting the use of medical cannabis.
The Israel Medical Association journal : IMAJ, April 2020
BACKGROUND: With the increased use of cannabis in the medicinal and recreational domains, it is becoming more important for physicians to better understand its harmful and beneficial effects. Although medical cannabis comes in several forms, the preferred route of administrati…
Canadian researchers found that the average training from physicians in training was 25% less than what they desired and that further training was paramount for them to engage in cannabis for therapeutic purposes (2020).
Journal of Clinical Medicine, 28 February 2020
Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in cannabis. While the safety of THC and cannabis has been extrapolated from millennia of recreational use, medical marijuana programs have increased exposure among medically complex individuals with comorbid co…
Gynecologic Oncology, 10 January 2020
Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) affect the human endocannabinoid system. Cannabinoids reduce chemotherapy induced nausea or vomiting (CINV) and neuropathic pain. Each state has its own regulations for medical and recreational cannabis use. Ef…
Complementary Therapies in Medicine, January 2020
Introduction: Over-the-counter and prescribed medical cannabis products are used by patients for various conditions including psychiatric disorders, pain management, and other neurodegenerative conditions.1 Despite this growing public interest and increasing legal availability…
A study published in BMC Family Practice sought to characterize the clinical practice characteristics of medical professionals who recommend cannabis.
The Journal of Pain, 9 November 2019
Use of cannabis to alleviate headache and migraine is relatively common, yet research on its effectiveness remains sparse. We sought to determine whether inhalation of cannabis decreases headache and migraine ratings as well as whether gender, type of cannabis (concentrate vs…
JAMA, 9 August 2019
Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the…
Therapeutic Advances in Medical Oncology, 1 August 2019
Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symp…